United States Patent 8,703,181: Scope, Claims, Expiration, and Patent Landscape for Liposomal Irinotecan

U.S. Patent No. 8,703,181 protects methods of treating tumors with injectable liposomes that encapsulate a cationic antineoplastic agent as a sucrose octasulfate salt. The most commercially important claim is claim 11, which is directed specifically to delivering irinotecan in this formulation. The patent does not broadly cover every liposomal irinotecan product. It requires the combination of an aqueous liposome interior, sucrose octasulfate salt formation, encapsulation in a lipid membrane, injection into a patient with a tumor, and a therapeutically effective dose.

The patent issued April 22, 2014, and is associated with the liposomal irinotecan product ONIVYDE, marketed by Ipsen Biopharmaceuticals, Inc. The principal patent-term endpoint associated with the family is March 30, 2027, subject to any applicable patent-term adjustment, patent-term extension, or terminal disclaimer reflected in the official patent record.[1][2]

What does U.S. Patent 8,703,181 cover?

The patent covers a drug-delivery method rather than a generic irinotecan molecule or every liposomal formulation.

Its central technical concept is the active loading of a cationic antineoplastic agent into the aqueous interior of a liposome by forming a poorly permeable sucrose octasulfate salt. The resulting formulation is intended to achieve high drug loading and prolonged release after intravenous administration.

The independent claims divide into two principal categories:

Claim	Protected subject matter	Commercial relevance
1	Injectable delivery of a cationic antineoplastic agent in a liposome containing sucrose octasulfate salt	Broad platform claim
11	Injectable delivery of irinotecan specifically encapsulated as a sucrose octasulfate salt	Core ONIVYDE-related claim
2	Drug-to-lipid molar-ratio thresholds	High-loading formulations
3	Neutral or anionic PEG-lipid derivatives	Long-circulating liposomes
4	Fluid formulation for parenteral administration	Injectable dosage forms
5-8	Microtubule stabilizers, taxanes, high loading, and exclusion of solubilizing aids	Taxane-specific platform coverage
9	Antibody-derived targeting moiety	Targeted liposomal delivery
12-13	Irinotecan-to-lipid molar ratios	Formulation-loading limitations
14	Fluid parenteral irinotecan formulation	Injectable product limitation
15-16	Minimum half-release times in mice and rats	Pharmacokinetic performance
17	At least 90% irinotecan retention after six months at 4-8°C	Stability and storage performance

How should claim 1 be construed?

Claim 1 requires each of the following elements:

A method of delivering an antineoplastic agent to a tumor.
Administration by injection.
A composition containing an aqueous medium.
A liposome within that aqueous medium.
An interior liposome space that is aqueous.
A lipid membrane separating the interior space from the external aqueous medium.
Sucrose octasulfate polyanion inside the liposome.
The sucrose octasulfate polyanion is present as a salt with a cationic antineoplastic agent.
Administration to a patient with a tumor.
Administration of an amount sufficient to deliver a therapeutically effective dose to the tumor.

The claim uses “comprising,” which generally leaves the claim open to additional excipients, lipids, buffers, targeting agents, and formulation components. A competing product could therefore contain ingredients not specifically recited in the claim and still fall within its scope.

The claim is narrower than a claim to “liposomal irinotecan” without structural limitations. A non-liposomal irinotecan product, a liposome that does not contain sucrose octasulfate, or a formulation in which the drug is not present as a sucrose octasulfate salt would not satisfy the literal requirements of claim 1.

What does claim 11 protect for irinotecan?

Claim 11 is the most commercially significant claim in the patent. It requires:

irinotecan as the antineoplastic agent;
an interior aqueous space;
a sucrose octasulfate salt of irinotecan in that space;
encapsulation by a membrane containing one or more lipids;
injection into a patient with a tumor; and
an amount sufficient to deliver a therapeutically effective dose.

This claim is directed to a specific drug-loading architecture. It does not cover ordinary intravenous irinotecan hydrochloride formulations, including conventional non-liposomal irinotecan products.

The claim also does not expressly require PEGylation, a particular lipid composition, a particular particle diameter, a specific tumor type, or a particular dosing schedule. Those features may be relevant to other patents, the product labeling, or infringement analysis, but they are not express limitations of claim 11.

What formulation features are protected by the dependent claims?

Drug-to-lipid loading ratio

Claims 2, 7, 12, and 13 impose molar-ratio thresholds between the antineoplastic agent and total lipid content.

For irinotecan, claim 12 recites ratios of at least approximately 0.05, 0.1, 0.2, or 0.3, while claim 13 narrows the requirement to at least 0.1. These limitations distinguish high-loading liposomes from formulations that encapsulate only small quantities of irinotecan relative to lipid.

The claim language creates a tiered fallback structure:

Ratio limitation	Claim coverage
At least about 0.05	Claim 12
At least about 0.1	Claims 12 and 13
At least about 0.2	Claim 12
At least about 0.3	Claim 12

A product that meets claim 11 but falls below the relevant loading ratio may avoid the corresponding dependent claim while remaining exposed under claim 11.

PEG-lipid content

Claim 3 covers liposomes containing either a neutral PEG-lipid derivative or an anionic PEG-lipid derivative. PEG-lipids commonly contribute to extended circulation and reduced uptake by the reticuloendothelial system.

This limitation is not required by claim 11. It becomes relevant where a competitor uses a PEGylated liposomal formulation and the composition otherwise satisfies the independent claim.

Parenteral formulation

Claims 4, 10, and 14 require a fluid pharmaceutical formulation for parenteral administration. Claim 11 already requires administration by injection, but claim 14 reinforces the formulation context for the irinotecan embodiment.

The claims therefore focus on injectable liquid products rather than dry powders, oral dosage forms, implantable depots, or non-injectable delivery systems.

Taxanes and microtubule stabilizers

Claims 5 through 8 extend the platform to microtubule-stabilizing agents and taxanes. These claims are separate from the irinotecan claims.

Claim 8 narrows the taxane embodiment by requiring that:

the interior space is essentially free of selected solubilizing aids;
the excluded aids include micelle-forming surfactants and cyclodextrins; and
the taxane does not contain a hydrophilic polymer moiety.

These limitations target formulations that achieve aqueous delivery through sucrose octasulfate salt loading rather than through conventional surfactant systems, cyclodextrins, or polymer-conjugated taxanes.

Antibody-based targeting

Claim 9 requires a targeting moiety that is a protein containing an antigen-binding sequence of an antibody. This claim covers a targeted liposome architecture layered onto the taxane embodiment.

It does not apply automatically to irinotecan products. The claim depends from claim 6 and therefore requires a taxane before the antibody-targeting limitation becomes operative.

Release and stability limitations

Claims 15 through 17 are important for product characterization and potential design-around analysis.

Claim 15 requires an irinotecan half-release time of at least 24 hours when administered into the bloodstream of a mouse. Claim 16 requires at least 48 hours in a rat. Claim 17 requires that at least 90% of irinotecan remain in the liposome after six months of storage at 4-8°C.

These claims introduce test-dependent limitations. Infringement analysis would require:

the specified animal model;
administration into the bloodstream;
a defined method for measuring release;
a reproducible calculation of half-release time; and
validated storage and assay data for the six-month stability period.

A formulation might infringe claim 11 without satisfying claims 15, 16, or 17.

When does U.S. Patent 8,703,181 lose exclusivity?

The principal patent-term date associated with the family is March 30, 2027.[1] The term is calculated from the applicable earliest effective nonprovisional or international filing date, not from the April 22, 2014 issue date.

Event	Date
Earliest effective priority date associated with the family	March 30, 2007
Patent issuance	April 22, 2014
Principal nominal expiration date	March 30, 2027
FDA approval of ONIVYDE	October 22, 2015
Expected loss of ordinary patent exclusivity	March 30, 2027, subject to statutory adjustments

Patent expiry does not automatically authorize a generic or follow-on product. A competitor must still obtain FDA approval, satisfy product-specific requirements, and avoid any unexpired related patents listed for the reference product.

What is the Orange Book status of U.S. Patent 8,703,181?

The patent is associated with ONIVYDE, an FDA-approved liposomal formulation of irinotecan hydrochloride trihydrate for use with fluorouracil and leucovorin in patients with metastatic pancreatic adenocarcinoma after progression following gemcitabine-based therapy.[2]

The Orange Book framework is relevant because it allows the holder of an approved drug application to list patents that claim:

the drug substance;
the drug product, including formulation or composition;
an approved method of using the drug.

U.S. Patent 8,703,181 is primarily a formulation and method-of-use patent. Its claims are not directed to the unconjugated irinotecan molecule. A generic sponsor seeking approval for a product that relies on the ONIVYDE reference listing could therefore face certification issues if the patent is listed for the applicable product and method.

Orange Book listing does not establish that every claim is valid, infringed, or enforceable. It creates a regulatory certification pathway under the Hatch-Waxman Act. A Paragraph IV certification can trigger patent litigation and, in appropriate circumstances, a 30-month stay of final approval under 21 U.S.C. § 355(j)(5)(B)(iii).[3]

What Paragraph IV challenges could affect ONIVYDE?

A generic sponsor could use several potential pathways:

Regulatory pathway	Likely product scope	Patent relevance
ANDA for conventional irinotecan	Non-liposomal product	Generally does not substitute for ONIVYDE and may not practice the claimed liposomal architecture
ANDA referencing ONIVYDE	Liposomal irinotecan product	Direct exposure to listed formulation and method patents
505(b)(2) application	Modified liposomal irinotecan or alternative formulation	Potential exposure to formulation, method, and pharmacokinetic claims
New drug application	Independent liposomal irinotecan product	Patent certifications and infringement risk depend on reliance on the reference product

A Paragraph IV challenge would likely focus on:

whether the claimed sucrose octasulfate salt architecture was obvious;
whether the asserted claims are adequately enabled across the full range of cationic antineoplastic agents;
whether the specification supports the claimed drug-to-lipid ratios;
whether the release and stability claims are definite and reproducible;
whether a competing formulation actually contains irinotecan as a sucrose octasulfate salt; and
whether the method claims are practiced by the proposed labeling.

Ordinary irinotecan generics do not necessarily create a direct substitute for ONIVYDE because ONIVYDE uses a liposomal delivery system and has a distinct clinical indication and administration regimen.[2]

Which companies are associated with the commercial patent position?

The patent family is associated with the liposomal irinotecan technology developed by Merrimack Pharmaceuticals. ONIVYDE was developed as MM-398 and later commercialized through licensing and acquisition arrangements involving Ipsen.[4]

Company	Role
Merrimack Pharmaceuticals	Developer and historical patent holder associated with MM-398 technology
Ipsen Biopharmaceuticals	Commercial and development partner associated with ONIVYDE
Servier	Global oncology company involved in later commercial arrangements relating to ONIVYDE outside or alongside Ipsen’s historical rights, depending on territory
Generic or 505(b)(2) sponsors	Potential future challengers or entrants

The commercial value of the patent is concentrated in the liposomal irinotecan product rather than in the broader taxane platform claims.

How strong is the patent estate for liposomal irinotecan?

The estate has meaningful technical coverage but is not impenetrable.

Strengths

The strongest features are:

a specific sucrose octasulfate loading mechanism;
direct coverage of irinotecan in claim 11;
injectable administration;
high drug-to-lipid ratios;
separate release and stability claims;
compatibility with PEG-lipid formulations;
method claims tied to treatment of tumors.

Claim 11 is commercially valuable because it combines a named drug with a distinctive formulation mechanism. A competitor would need to avoid at least one claim element, invalidate the claim, or obtain a license to reduce risk.

Vulnerabilities

Potential weaknesses include:

method-claim dependence on actual clinical administration;
possible prior art involving ion-gradient loading and polyanion salts;
potential enablement disputes across the broad antineoplastic-agent language of claim 1;
factual disputes over whether irinotecan exists as the claimed sucrose octasulfate salt inside the liposome;
measurement disputes involving half-release time;
possible noninfringement based on alternative internal counterions or loading chemistry.

The patent is stronger against a product that copies the ONIVYDE architecture than against a product using a different internal loading agent, different salt chemistry, or a non-liposomal delivery system.

What manufacturing and intellectual-property barriers exist?

The principal manufacturing barrier is reproducible active loading of irinotecan into liposomes while maintaining:

high encapsulation efficiency;
acceptable particle-size distribution;
controlled release;
low leakage during storage;
sufficient stability at refrigerated temperatures;
batch-to-batch consistency; and
clinical bioequivalence or therapeutic comparability.

A design-around formulation might use a different polyanion, a different counterion, a different pH-gradient loading method, or a non-liposomal depot. Each approach creates development risks, including altered pharmacokinetics, toxicity, release behavior, and clinical performance.

The patent does not by itself block all manufacturing methods for liposomal irinotecan. It creates the highest risk where the manufacturing process produces the claimed internal sucrose octasulfate salt and the commercial product is administered by injection for tumor treatment.

What litigation and settlement issues matter?

The relevant litigation questions are product-specific:

Whether the challenger is seeking approval for liposomal irinotecan or conventional irinotecan.
Whether the challenged patent is listed for the referenced ONIVYDE product.
Whether the sponsor files a Paragraph IV, Paragraph III, or Section VIII certification.
Whether the proposed labeling includes an indication or dosing instruction that practices the method claims.
Whether a 30-month stay is triggered.
Whether the parties resolve the dispute through a license, launch-date settlement, or consent judgment.

A conventional irinotecan ANDA generally presents a different risk profile from an ONIVYDE follow-on. A follow-on liposomal product is more likely to face direct exposure to the formulation and administration limitations in claims 11 through 17.

How does U.S. Patent 8,703,181 compare with competing patent categories?

Patent category	Typical protected subject matter	Relationship to 8,703,181
Drug-substance patent	Irinotecan chemical compound	Separate and generally earlier-expiring category
Liposome-composition patent	Lipid identity, particle size, PEGylation, encapsulation	May overlap with dependent claims but can provide separate barriers
Loading-method patent	Ion gradients, internal salts, pH-driven loading	May cover manufacturing even when the treatment claims do not
Method-of-use patent	Pancreatic cancer, combination therapy, dosing schedules	Can remain relevant after formulation claims expire
Stability patent	Refrigerated storage and retention characteristics	Similar to claim 17
Manufacturing-process patent	Scale-up, purification, sterile filling	May create practical barriers independent of treatment claims

A complete freedom-to-operate review must evaluate the entire ONIVYDE family, continuation patents, formulation patents, method-of-use patents, and manufacturing patents. U.S. Patent 8,703,181 is important, but it should not be treated as the complete patent estate.

What are the principal generic-entry scenarios?

Scenario 1: Conventional irinotecan entry

A conventional irinotecan generic enters without practicing the liposomal sucrose octasulfate formulation. It competes with standard irinotecan products rather than directly substituting for ONIVYDE.

Scenario 2: Liposomal irinotecan after patent expiry

A follow-on sponsor launches after March 30, 2027, assuming no enforceable related patent remains and FDA approval is obtained. This is the clearest pathway to direct ONIVYDE competition.

Scenario 3: Early Paragraph IV challenge

A sponsor challenges the patent before expiry and argues invalidity or noninfringement. The reference product sponsor may pursue district-court litigation and seek a 30-month stay.

Scenario 4: Design-around liposomal product

A sponsor uses a different internal salt, loading agent, or release mechanism. This reduces literal infringement risk but increases formulation-development and regulatory-comparability risk.

Scenario 5: Licensed entry

A challenger negotiates a license or settlement that permits launch on an agreed date before patent expiry. The economic value would depend on launch timing, territory, royalty structure, and any related patents.

Key Takeaways

U.S. Patent 8,703,181 is a liposomal drug-delivery patent focused on sucrose octasulfate loading.
Claim 11 is the key irinotecan claim and directly targets the formulation architecture associated with ONIVYDE.
The patent does not cover conventional, non-liposomal irinotecan generics.
Claims 15 through 17 add animal release-performance and refrigerated-storage limitations but are narrower than claim 11.
The associated principal patent-term date is March 30, 2027.
A liposomal irinotecan competitor faces greater risk than a conventional irinotecan ANDA sponsor.
The strongest design-around opportunities involve alternative internal loading chemistry or a non-liposomal delivery system.
The patent should be analyzed with related continuation, formulation, method-of-use, and manufacturing patents before making a launch or licensing decision.
ONIVYDE’s commercial exposure is concentrated in the patent-protected liposomal irinotecan formulation and its approved pancreatic-cancer use.

FAQs

Does U.S. Patent 8,703,181 cover ordinary irinotecan hydrochloride?

No. The asserted claims require a liposome containing irinotecan as a sucrose octasulfate salt. Conventional non-liposomal irinotecan hydrochloride generally does not satisfy those structural limitations.

Can a competitor avoid the patent by removing PEG from the liposome?

Potentially, but not automatically. PEG-lipid content is required by claim 3, not by claim 11. Removing PEG may avoid claim 3 while leaving the competitor exposed under claim 11 if the remaining elements are present.

Is claim 17 a general stability claim for all irinotecan products?

No. Claim 17 requires at least 90% irinotecan retention in the liposome after six months at 4-8°C. It applies only within the claim 14 irinotecan formulation context and does not cover all irinotecan products.

Does patent expiration permit immediate FDA substitution for ONIVYDE?

No. Patent expiry removes the patent barrier but does not provide FDA approval or automatic pharmacy substitution. The follow-on product must obtain approval through an applicable FDA pathway.

Are biosimilar rules relevant to ONIVYDE?

No. ONIVYDE is a small-molecule irinotecan product with a liposomal delivery system, not a biologic subject to the biosimilar pathway under the Public Health Service Act. Follow-on applicants would generally use an ANDA, 505(b)(2), or independent NDA pathway.

References

United States Patent and Trademark Office. (2014). U.S. Patent No. 8,703,181, Liposomal formulations containing sucrose octasulfate.
U.S. Food and Drug Administration. (2024). ONIVYDE (irinotecan liposome injection) prescribing information.
Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 355(j).
Ipsen. (2017). Ipsen completes acquisition of Merrimack’s ONIVYDE rights.

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	1746976	⤷ Start Trial	300885	Netherlands	⤷ Start Trial
European Patent Office	1746976	⤷ Start Trial	122017000042	Germany	⤷ Start Trial
European Patent Office	1746976	⤷ Start Trial	CA 2017 00030	Denmark	⤷ Start Trial
European Patent Office	1746976	⤷ Start Trial	LUC00026	Luxembourg	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 8,703,181

Summary for Patent: 8,703,181